BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, each CureVac share will be exchanged for approximately $5 …